Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2021-03-16 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
《投资者关系管理制度》
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management System" for Zhuhai Sailong Pharmaceutical Co., Ltd. It outlines the company's policies, principles, organizational structure, and procedures for managing investor relations. The content focuses on governance, communication with investors, compliance with laws and regulations, and internal coordination for investor relations activities. There are no financial statements, earnings data, audit opinions, or regulatory filings of financial results. The document is a governance and procedural manual related to investor relations management rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2021-03-16 Chinese
《对外担保管理制度》
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '对外担保管理制度' (External Guarantee Management System) of Zhuhai Sailong Pharmaceutical Co., Ltd. It outlines the company's procedures, responsibilities, and governance related to providing external guarantees, including approval processes, risk management, and disclosure obligations. It references relevant laws, company bylaws, and regulatory requirements, but it is not a financial report, earnings release, or announcement. It is a governance-related document detailing internal rules and procedures for managing external guarantees. Therefore, it fits best under Governance Information (CGR). The document length (6299 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2021-03-16 Chinese
珠海赛隆药业股份有限公司独立董事提名人声明（潘传云）
Board/Management Information Classification · 100% confidence The document is a public statement by a nominator regarding the nomination of an independent director candidate for the company's board. It details the qualifications, compliance with regulatory requirements, and independence of the nominee. There is no financial data, no discussion of financial results, no mention of shareholder voting results, or any other report type. This is clearly related to board/management information, specifically about a board director nomination. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length and content confirm it is not a brief announcement or a report publication notice, but a detailed nomination statement.
2021-03-16 Chinese
珠海赛隆药业股份有限公司独立董事提名人声明（陈小辛）
Board/Management Information Classification · 95% confidence The document is a public statement by a nominator regarding the nomination of an independent director candidate for the company's board. It details the candidate's qualifications, compliance with regulatory requirements, and independence criteria. There is no financial data, no report of financial results, no voting results, no management changes announcement, nor any mention of a meeting or shareholder vote results. The document is a formal declaration related to board/management information, specifically about the nomination of a board member. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is sufficient and contains detailed statements about the nominee's qualifications and compliance, confirming it is not a brief announcement or a regulatory filing. Hence, the classification is MANG with high confidence.
2021-03-16 Chinese
珠海赛隆药业股份有限公司独立董事候选人声明（张维）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Zhuhai Sailong Pharmaceutical Co., Ltd. It contains statements about the candidate's qualifications, compliance with laws and regulations, and independence criteria. There is no financial data, no discussion of company financial performance, no voting results, no management changes, and no mention of report publication. The document is a formal declaration related to board/management information, specifically about an independent director candidate's qualifications and compliance. Therefore, it fits best under Board/Management Information (MANG). The document length is about 5,293 characters, which is sufficient for a full declaration rather than a brief announcement or certification. Hence, the classification is MANG with high confidence.
2021-03-16 Chinese
关于参加独立董事培训并取得独立董事资格证书的承诺函
Regulatory Filings Classification · 95% confidence The document is a written commitment letter from an independent director candidate regarding participation in training and obtaining a qualification certificate as required by the Shenzhen Stock Exchange rules. It references regulatory requirements and a board resolution but does not contain financial data, report content, or announcements of voting results. It is a regulatory compliance statement related to board/management qualifications but not an announcement of board changes or management appointments. It does not fit into categories like MANG (board changes), DVA (voting results), or RPA (report publication). The best fit is Regulatory Filings (RNS) as it is a compliance-related filing that does not neatly fit other categories.
2021-03-16 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.